{"entity":{"id":"lymphoma-ev-manufacturing-time-as-a-trial-endpoint","kind":"idea","name":"Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote","aka":["Vein-to-vein time as a CAR-T endpoint","Manufacturing interval in cell therapy trials"],"tldr":"The best explanation for why one second-line CAR-T trial failed when two succeeded is how long the cells took to make. That interval is almost never a reported endpoint.","summary":"This is a cheap idea with a large effect on interpretation. The cross-trial inference that manufacturing time explains BELINDA is the best available explanation for a 322-patient randomised failure, and it remains an inference because the data to test it were not collected as endpoints. Rapid-manufacture and point-of-care products are entering trials now, which makes the measurement urgent rather than retrospective.","asOf":"2026-10-01","links":[],"tags":["lymphoma-evidence"],"related":["lymphoma-roadmap"],"cancers":["dlbcl","non-hodgkin-lymphoma","follicular-lymphoma"],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":["axicabtagene-ciloleucel","tisagenlecleucel","lisocabtagene-maraleucel"],"companies":[],"institutions":[],"pathways":[],"terms":["bridging-therapy","lymphodepletion","lymphoma-tx-car-t-pathway"],"trials":["belinda","zuma-7","transform","transcend-nhl-001"],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-trial-design","b-real-world-evidence"],"keyPapers":["paper-belinda-tisagenlecleucel-second-line-nejm-2022","paper-transcend-nhl-001-liso-cel-lancet-2020","paper-zuma-7-axi-cel-second-line-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"The interval between apheresis and infusion, and what is given during it, is a determinant of CAR-T outcome large enough to change trial results, and reporting it as a prespecified endpoint would improve both trial interpretation and clinical delivery.","rationale":"BELINDA randomised 322 patients to tisagenlecleucel or salvage chemotherapy with transplant in the second line and found median event-free survival of 3.0 months in both arms, while ZUMA-7 and TRANSFORM, testing the other two products in the same setting, were positive. The median time from leukapheresis to infusion in BELINDA was 52 days, and 25.9 per cent of the CAR-T group had progressed by week 6 against 13.8 per cent of the comparator group. TRANSCEND NHL 001 reported that 75 of 344 patients who underwent leukapheresis never received the product, which is attrition a response rate does not show.","test":"Require trials of autologous cell therapy to prespecify and report the distribution of the apheresis-to-infusion interval, the proportion of enrolled patients who never receive the product and why, and an intention-to-treat analysis from apheresis rather than from infusion. Then test, in a randomised comparison or a registry with sufficient variation, whether shortening the interval improves outcomes.","maturity":"early-clinical","actor":"regulator","cost":"small","horizonYears":4},"route":"/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"}],"term":[{"id":"bridging-therapy","kind":"term","name":"Bridging therapy","route":"/terms/bridging-therapy/"},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/"},{"id":"lymphoma-tx-car-t-pathway","kind":"term","name":"The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting","route":"/terms/lymphoma-tx-car-t-pathway/"}],"trial":[{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/"},{"id":"transcend-nhl-001","kind":"trial","name":"TRANSCEND NHL 001","route":"/trials/transcend-nhl-001/"},{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"paper":[{"id":"paper-transcend-nhl-001-liso-cel-lancet-2020","kind":"paper","name":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","route":"/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/"},{"id":"paper-belinda-tisagenlecleucel-second-line-nejm-2022","kind":"paper","name":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","route":"/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/"}]}}